Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple MyelomaFaiz Anwer, Christy Samaras, Sabina Saeed et al.|Clinical Lymphoma Myeloma & Leukemia|2019Cited by 23
Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model FrameworkWeijia Wang, Steve D’Amato, Edward Li et al.|JCO Oncology Practice|2021Cited by 20
Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysisAli McBride, Weijia Wang, Kim Campbell et al.|Journal of Managed Care & Specialty Pharmacy|2021Cited by 11
Hydration Requirements with Emetogenic Chemotherapy: Granisetron Extended-Release Subcutaneous Versus PalonosetronJeffrey Vacirca, Ali McBride, Dennis L. Caruana et al.|Future Oncology|2018Cited by 10
HSR21-073: Febrile Neutropenia Outcomes Among Patients With Breast Cancer and Non-Hodgkin’s Lymphoma Receiving Pegfilgrastim Prophylaxis: A Real-World Analysis of Commercial and Medicare Claims From 2017-2018Weijia Wang, Ali McBride, Edward Li et al.|Journal of the National Comprehensive Cancer Network|2021Cited by 1